<DOC>
	<DOCNO>NCT00688909</DOCNO>
	<brief_summary>This study evaluate whether patient intolerant discontinue anastrozole due grade 2-3 arthralgia-myalgia decrease rheumatological symptom take letrozole</brief_summary>
	<brief_title>Rheumatological Evaluation Anastrozole Letrozole Adjuvant Treatment Post-menopausal Women With Breast Cancer</brief_title>
	<detailed_description>This multi-center prospective non-randomized single arm , open label trial postmenopausal HR positive early breast cancer patient experience grade 2-3 arthralgia-myalgia anastrozole , result discontinuation anastrozole . After 2-3 week period without aromatase inhibitor treatment , eligible patient initiate letrozole treatment dose 2.5mg per day duration 24 week . If patient breast cancer recurrence intolerant letrozole 24 week period , drug discontinue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Postmenopausal woman HR+ early stage breast cancer time initial diagnosis . For study purpose , postmenopausal define : Age ≥ 50 amenorrheic 12 month . Age ≥ 50 amenorrheic 3 month receive adjuvant chemotherapy . Age &lt; 50 amenorrheic 12 month . Prior bilateral oophorectomy . Prior hysterectomy postmenopausal level FSH , LH , estradiol per local institutional standard . Age &gt; 55 prior hysterectomy . 2 . Patients intolerant discontinue anastrozole 23 week prior study entry give adjuvant treatment HR+ early stage breast cancer due grade 23 ( NCICTCAE V3 ) arthralgiamyalgia . 3 . Hormone receptorpositive tumor define institutional standard . 4 . ECOG performance status 0 , 1 , 2 5 . Consent participate trial . 1 . Postmenopausal woman HR+ metastatic locally relapse breast cancer exclude chest wall recurrence evidence systemic disease . 2 . Recent history pain associate nontraumatic bone fracture . 3 . Pain require chronic use analgesic ( due reason ) . 4 . History rheumatological disease except osteoarthritis . 5 . Prior hormonal therapy AIs anastrozole . 6 . Systemic hormone replacement therapy ( HRT ) less 4 week study entry Estring® , Vagifem® low dose estrogen vaginal cream . 7 . Concomitant disease significantly affect quality life . 8 . Patient unable complete self administer questionnaire . 9 . Patients unable sign consent form . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant treatment post menopausal woman</keyword>
	<keyword>letrozole</keyword>
	<keyword>arthralgia-myalgia</keyword>
</DOC>